These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35544743)

  • 1. Clinical Features of Kawasaki Disease With Atlantoaxial Rotatory Fixation.
    Michihata N; Suzuki T; Honda A; Oka I; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
    Pediatr Infect Dis J; 2022 Aug; 41(8):626-630. PubMed ID: 35544743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan.
    Takekoshi N; Kitano N; Takeuchi T; Suenaga T; Kakimoto N; Suzuki T; Kada TT; Shibuta S; Tachibana S; Murayama Y; Yamaga H; Suzuki H
    JAMA Netw Open; 2022 Jun; 5(6):e2216642. PubMed ID: 35696166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between intravenous immunoglobulin dose and outcomes in patients with acute Kawasaki disease.
    Michihata N; Suzuki T; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
    Eur J Pediatr; 2022 Oct; 181(10):3607-3615. PubMed ID: 35925450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
    Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between aspirin dose and outcomes in patients with acute Kawasaki disease: a nationwide retrospective cohort study in Japan.
    Suzuki T; Michihata N; Hashimoto Y; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
    Eur J Pediatr; 2024 Jan; 183(1):415-424. PubMed ID: 37917176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
    Li W; He X; Zhang L; Wang Z; Wang Y; Lin H; Yuan J; Xie X; Qin Y; Huang P
    Cardiovasc Ther; 2021; 2021():6660407. PubMed ID: 34239607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-containing versus sodium-trace preparations of IVIG for children with Kawasaki disease in the acute phase.
    Suzuki T; Michihata N; Aso S; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
    Eur J Pediatr; 2021 Nov; 180(11):3279-3286. PubMed ID: 33973071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low- versus high-concentration intravenous immunoglobulin for children with Kawasaki disease in the acute phase.
    Suzuki T; Michihata N; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
    Int J Rheum Dis; 2022 May; 25(5):576-583. PubMed ID: 35258165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
    Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
    Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more.
    Suzuki T; Michihata N; Yoshikawa T; Hata T; Matsui H; Fushimi K; Yasunaga H
    Eur J Pediatr; 2020 Dec; 179(12):1901-1907. PubMed ID: 32862279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
    Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology and Risk Factors for Giant Coronary Artery Aneurysms Identified After Acute Kawasaki Disease.
    Masuda H; Ae R; Koshimizu TA; Matsumura M; Kosami K; Hayashida K; Makino N; Matsubara Y; Sasahara T; Nakamura Y
    Pediatr Cardiol; 2021 Apr; 42(4):969-977. PubMed ID: 33682062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease.
    Amano Y; Akazawa Y; Yasuda J; Yoshino K; Kojima K; Kobayashi N; Matsuzaki S; Nagasaki M; Kawai Y; Minegishi N; Ishida N; Motoki N; Hachiya A; Nakazawa Y; Yamamoto M; Koike K; Takeshita T
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):34. PubMed ID: 31269967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Difference in Risk Factors for Subtypes of Acute Cardiac Lesions Resulting from Kawasaki Disease.
    Yamashita M; Ae R; Yashiro M; Aoyama Y; Sano T; Makino N; Nakamura Y
    Pediatr Cardiol; 2017 Feb; 38(2):375-380. PubMed ID: 27878631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated D-dimer level is a risk factor for coronary artery lesions accompanying intravenous immunoglobulin-unresponsive Kawasaki disease.
    Masuzawa Y; Mori M; Hara T; Inaba A; Oba MS; Yokota S
    Ther Apher Dial; 2015 Apr; 19(2):171-7. PubMed ID: 25257673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
    Platt B; Belarski E; Manaloor J; Ofner S; Carroll AE; John CC; Wood JB
    JAMA Netw Open; 2020 Jan; 3(1):e1918565. PubMed ID: 31899532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Appearance of Principal Symptoms of Kawasaki Disease is a Risk Factor for Intravenous Immunoglobulin Resistance.
    Tajima M; Shiozawa Y; Kagawa J
    Pediatr Cardiol; 2015 Aug; 36(6):1159-65. PubMed ID: 25753685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
    Wang J; Chen H; Shi H; Zhang X; Shao Y; Hang B; Xu Z; Rong X; Chu M; Qiu H
    Pediatr Rheumatol Online J; 2020 Jun; 18(1):48. PubMed ID: 32527316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease.
    Yanagimoto K; Nomura Y; Masuda K; Hirabayashi M; Morita Y; Yoshishige M; Ueno K; Eguchi T; Kawano Y
    Int Arch Allergy Immunol; 2014; 164(2):83-8. PubMed ID: 24903098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.